公开(公告)号：US11291716B2

公开(公告)日：2022-04-05

申请号：US17459313

申请日：2021-08-27

Applicant: VIRION THERAPEUTICS, LLC ,  THE WISTAR INSTITUTE

Inventor： Hildegund C J Ertl ,  Colin Stephen Magowan

IPC: A61K39/00 ,  A61K39/395 ,  A61K38/00 ,  C07K16/28 ,  C12Q1/68 ,  A61K39/29 ,  C12N15/86 ,  C12N7/00 ,  A61P31/12

Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

公开(公告)号：US20230063089A1

公开(公告)日：2023-03-02

申请号：US17790259

申请日：2021-01-08

Applicant: VIRION THERAPEUTICS, LLC ,  THE WISTAR INSTITUTE

Inventor： Hildegund CJ ERTL ,  Colin Stephen MAGOWAN

IPC: A61K39/29 ,  C12N15/86 ,  A61P31/12

Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

公开(公告)号：US11850282B2

公开(公告)日：2023-12-26

申请号：US17679356

申请日：2022-02-24

Applicant: Virion Therapeutics, LLC ,  The Wistar Institute

Inventor： Hildegund C J Ertl ,  Colin Stephen Magowan

IPC: C12N15/86 ,  C12N7/00 ,  C12N15/62 ,  C12N15/861 ,  A61K39/29 ,  A61P31/12 ,  A61K39/00

CPC classification number: A61K39/292 ,  A61P31/12 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/53 ,  C12N2710/10343 ,  C12N2730/10122 ,  C12N2730/10134

Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

公开(公告)号：US20210393770A1

公开(公告)日：2021-12-23

申请号：US17459313

申请日：2021-08-27

Applicant: VIRION THERAPEUTICS, LLC ,  THE WISTAR INSTITUTE

Inventor： Hildegund CJ ERTL ,  Colin Stephen MAGOWAN

IPC: A61K39/29 ,  C12N15/86 ,  A61P31/12 ,  C12N7/00

Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

公开(公告)号：US20240269271A1

公开(公告)日：2024-08-15

申请号：US18407567

申请日：2024-01-09

Applicant: VIRION THERAPEUTICS, LLC ,  THE WISTAR INSTITUTE

Inventor： Hildegund CJ Ertl ,  Sue L. Currie ,  Andrew D. Luber

IPC: A61K39/39 ,  A61K39/00 ,  A61K39/12 ,  C07K14/005 ,  C07K14/47

CPC classification number: A61K39/39 ,  A61K39/12 ,  C07K14/005 ,  C07K14/47 ,  A61K2039/5256 ,  A61K2039/55516 ,  A61K2039/585 ,  C07K2319/00 ,  C12N2710/20022 ,  C12N2710/20034

Abstract: Disclosed herein are compositions for increasing the immunogenicity of a vaccine antigen and methods of inducing an immune response in a subject using the compositions described herein. Disclosed herein are compositions for a therapeutic vaccine to HPV-associated cancers and methods of inducing an immune response to HPV in a subject using the compositions described herein.

公开(公告)号：US20240091347A1

公开(公告)日：2024-03-21

申请号：US18492945

申请日：2023-10-24

Applicant: Virion Therapeutics, LLC ,  The Wistar Institute

Inventor： Hildegund CJ ERTL ,  Colin Stephen MAGOWAN

IPC: A61K39/29 ,  A61P31/12 ,  C12N7/00 ,  C12N15/86

CPC classification number: A61K39/292 ,  A61P31/12 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/53

Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

公开(公告)号：US20220175913A1

公开(公告)日：2022-06-09

申请号：US17679356

申请日：2022-02-24

Applicant: Virion Therapeutics, LLC ,  The Wistar Institute

Inventor： Hildegund CJ ERTL ,  Colin Stephen MAGOWAN

IPC: A61K39/29 ,  A61P31/12 ,  C12N7/00 ,  C12N15/86

Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.